{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:45:40Z","timestamp":1792507540089,"version":"4.5.0"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/nrc3844","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T03:01:20Z","timestamp":1419303680000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":744,"title":["VHL, the story of a tumour suppressor gene"],"prefix":"10.1038","volume":"15","author":[{"given":"Lucy","family":"Gossage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn R.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"BFnrc3844_CR1","first-page":"141","volume":"14","author":"ET Collins","year":"1894","unstructured":"Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably primarily retinal, affecting both eyes). Trans. Ophthal. Soc. UK 14, 141\u2013149 (1894).","journal-title":"Trans. Ophthal. Soc. UK"},{"key":"BFnrc3844_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01994821","volume":"59","author":"E Von Hippel","year":"1904","unstructured":"Von Hippel, E. Ueber eine sehr seltene Erkrankung der Netzhaut. Albrecht Graefes Arch. Ophthal. 59, 83\u2013106 (1904) (in German).","journal-title":"Albrecht Graefes Arch. Ophthal."},{"key":"BFnrc3844_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1755-3768.1926.tb07786.x","volume":"4","author":"A Lindau","year":"1927","unstructured":"Lindau, A. Zur frage der angiomatosis retinae und ihrer hirncomplikation. Acta Ophthalmol. Scand. 4, 193\u2013226 (1927) (in German).","journal-title":"Acta Ophthalmol. Scand."},{"key":"BFnrc3844_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher, E. R., Neumann, H. P. & Richard, S. von Hippel\u2013Lindau disease: a clinical and scientific review. Eur. J. Hum. Genet. 19, 617\u2013623 (2011).","journal-title":"Eur. J. Hum. Genet."},{"key":"BFnrc3844_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9343(64)90107-X","volume":"36","author":"KL Melmon","year":"1964","unstructured":"Melmon, K. L. & Rosen, S. W. Lindau's disease. Review of the literature and study of a large kindred. Am. J. Med. 36, 595\u2013617 (1964).","journal-title":"Am. J. Med."},{"key":"BFnrc3844_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF00204184","volume":"87","author":"GM Glenn","year":"1991","unstructured":"Glenn, G. M. et al. Von Hippel\u2013Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum. Genet. 87, 207\u2013210 (1991).","journal-title":"Hum. Genet."},{"key":"BFnrc3844_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-Y","volume":"337","author":"HP Neumann","year":"1991","unstructured":"Neumann, H. P. & Wiestler, O. D. Clustering of features of von Hippel\u2013Lindau syndrome: evidence for a complex genetic locus. Lancet 337, 1052\u20131054 (1991).","journal-title":"Lancet"},{"key":"BFnrc3844_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen, F. et al. Germline mutations in the von Hippel\u2013Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66\u201375 (1995).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","volume":"10","author":"MA Hoffman","year":"2001","unstructured":"Hoffman, M. A. et al. von Hippel\u2013Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019\u20131027 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3844_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.27.5.311","volume":"27","author":"ER Maher","year":"1990","unstructured":"Maher, E. R., Yates, J. R. & Ferguson-Smith, M. A. Statistical analysis of the two stage mutation model in von Hippel\u2013Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J. Med. Genet. 27, 311\u2013314 (1990).","journal-title":"J. Med. Genet."},{"key":"BFnrc3844_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif, F. et al. Identification of the von Hippel\u2013Lindau disease tumor suppressor gene. Science 260, 1317\u20131320 (1993).","journal-title":"Science"},{"key":"BFnrc3844_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/jnci\/81.14.1097","volume":"81","author":"K Tory","year":"1989","unstructured":"Tory, K. et al. Specific genetic change in tumors associated with von Hippel\u2013Lindau disease. J. Natl Cancer Inst. 81, 1097\u20131101 (1989).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc3844_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00218913","volume":"93","author":"PA Crossey","year":"1994","unstructured":"Crossey, P. A. et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel\u2013Lindau disease: analysis of allele loss in VHL tumours. Hum. Genet. 93, 53\u201358 (1994).","journal-title":"Hum. Genet."},{"key":"BFnrc3844_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/327721a0","volume":"327","author":"B Zbar","year":"1987","unstructured":"Zbar, B., Brauch, H., Talmadge, C. & Linehan, M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327, 721\u2013724 (1987).","journal-title":"Nature"},{"key":"BFnrc3844_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Jr. Tumour suppression by the human von Hippel\u2013Lindau gene product. Nature Med. 1, 822\u2013826 (1995).","journal-title":"Nature Med."},{"key":"BFnrc3844_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1073\/pnas.95.3.993","volume":"95","author":"A Pause","year":"1998","unstructured":"Pause, A., Lee, S., Lonergan, K. M. & Klausner, R. D. The von Hippel\u2013Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl Acad. Sci. USA 95, 993\u2013998 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR17","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/sj.onc.1202473","volume":"18","author":"C Blankenship","year":"1999","unstructured":"Blankenship, C., Naglich, J. G., Whaley, J. M., Seizinger, B. & Kley, N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18, 1529\u20131535 (1999).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR18","doi-asserted-by":"publisher","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","volume":"95","author":"O Iliopoulos","year":"1998","unstructured":"Iliopoulos, O., Ohh, M. & Kaelin, W. G. Jr. pVHL19 is a biologically active product of the von Hippel\u2013Lindau gene arising from internal translation initiation. Proc. Natl Acad. Sci. USA 95, 11661\u201311666 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR19","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","volume":"95","author":"A Schoenfeld","year":"1998","unstructured":"Schoenfeld, A., Davidowitz, E. J. & Burk, R. D. A second major native von Hippel\u2013Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl Acad. Sci. USA 95, 8817\u20138822 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1126\/science.7660122","volume":"269","author":"DR Duan","year":"1995","unstructured":"Duan, D. R. et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269, 1402\u20131406 (1995).","journal-title":"Science"},{"key":"BFnrc3844_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.7660130","volume":"269","author":"A Kibel","year":"1995","unstructured":"Kibel, A., Iliopoulos, O., DeCaprio, J. A. & Kaelin, W. G. Jr. Binding of the von Hippel\u2013Lindau tumor suppressor protein to Elongin B and C. Science 269, 1444\u20131446 (1995).","journal-title":"Science"},{"key":"BFnrc3844_CR22","first-page":"4544","volume":"55","author":"T Kishida","year":"1995","unstructured":"Kishida, T., Stackhouse, T. M., Chen, F., Lerman, M. I. & Zbar, B. Cellular proteins that bind the von Hippel\u2013Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res. 55, 4544\u20134548 (1995).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.284.5413.455","volume":"284","author":"CE Stebbins","year":"1999","unstructured":"Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. Structure of the VHL\u2013ElonginC\u2013ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455\u2013461 (1999).","journal-title":"Science"},{"key":"BFnrc3844_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/MCB.18.2.732","volume":"18","author":"KM Lonergan","year":"1998","unstructured":"Lonergan, K. M. et al. Regulation of hypoxia-inducible mRNAs by the von Hippel\u2013Lindau tumor suppressor protein requires binding to complexes containing elongins B\/C and Cul2. Mol. Cell. Biol. 18, 732\u2013741 (1998).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1126\/science.284.5414.657","volume":"284","author":"T Kamura","year":"1999","unstructured":"Kamura, T. et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284, 657\u2013661 (1999).","journal-title":"Science"},{"key":"BFnrc3844_CR26","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","volume":"94","author":"A Pause","year":"1997","unstructured":"Pause, A. et al. The von Hippel\u2013Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156\u20132161 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR27","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1073\/pnas.97.15.8507","volume":"97","author":"AR Schoenfeld","year":"2000","unstructured":"Schoenfeld, A. R., Davidowitz, E. J. & Burk, R. D. Elongin BC complex prevents degradation of von Hippel\u2013Lindau tumor suppressor gene products. Proc. Natl Acad. Sci. USA 97, 8507\u20138512 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR28","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genet. 45, 860\u2013867 (2013).","journal-title":"Nature Genet."},{"key":"BFnrc3844_CR29","doi-asserted-by":"publisher","first-page":"12436","DOI":"10.1073\/pnas.96.22.12436","volume":"96","author":"K Iwai","year":"1999","unstructured":"Iwai, K. et al. Identification of the von Hippel\u2013Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl Acad. Sci. USA 96, 12436\u201312441 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR30","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1101\/gad.13.14.1822","volume":"13","author":"J Lisztwan","year":"1999","unstructured":"Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel\u2013Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13, 1822\u20131833 (1999).","journal-title":"Genes Dev."},{"key":"BFnrc3844_CR31","doi-asserted-by":"publisher","first-page":"25733","DOI":"10.1074\/jbc.M002740200","volume":"275","author":"ME Cockman","year":"2000","unstructured":"Cockman, M. E. et al. Hypoxia inducible factor-\u03b1 binding and ubiquitylation by the von Hippel\u2013Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733\u201325741 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3844_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the \u03b2-domain of the von Hippel\u2013Lindau protein. Nature Cell Biol. 2, 423\u2013427 (2000).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3844_CR33","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","volume":"19","author":"K Tanimoto","year":"2000","unstructured":"Tanimoto, K., Makino, Y., Pereira, T. & Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1\u03b1 by the von Hippel\u2013Lindau tumor suppressor protein. EMBO J. 19, 4298\u20134309 (2000).","journal-title":"EMBO J."},{"key":"BFnrc3844_CR34","first-page":"1358","volume":"55","author":"S Wizigmann-Voos","year":"1995","unstructured":"Wizigmann-Voos, S., Breier, G., Risau, W. & Plate, K. H. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel\u2013Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55, 1358\u20131364 (1995).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR35","first-page":"4233","volume":"54","author":"A Takahashi","year":"1994","unstructured":"Takahashi, A. et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 54, 4233\u20134237 (1994).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1620\/tjem.173.355","volume":"173","author":"K Sato","year":"1994","unstructured":"Sato, K. et al. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J. Exp. Med. 173, 355\u2013360 (1994).","journal-title":"Tohoku J. Exp. Med."},{"key":"BFnrc3844_CR37","doi-asserted-by":"publisher","first-page":"10589","DOI":"10.1073\/pnas.93.20.10589","volume":"93","author":"JR Gnarra","year":"1996","unstructured":"Gnarra, J. R. et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA 93, 10589\u201310594 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR38","doi-asserted-by":"publisher","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","volume":"93","author":"O Iliopoulos","year":"1996","unstructured":"Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel\u2013Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595\u201310599 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"BFnrc3844_CR40","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nature00767","volume":"417","author":"WC Hon","year":"2002","unstructured":"Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL. Nature 417, 975\u2013978 (2002).","journal-title":"Nature"},{"key":"BFnrc3844_CR41","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1126\/science.1073440","volume":"296","author":"JH Min","year":"2002","unstructured":"Min, J. H. et al. Structure of an HIF-1\u03b1\u2013pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886\u20131889 (2002).","journal-title":"Science"},{"key":"BFnrc3844_CR42","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.1066373","volume":"294","author":"RK Bruick","year":"2001","unstructured":"Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337\u20131340 (2001).","journal-title":"Science"},{"key":"BFnrc3844_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan, M. et al. HIF\u03b1 targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464\u2013468 (2001).","journal-title":"Science"},{"key":"BFnrc3844_CR44","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola, P. et al. Targeting of HIF\u03b1 to the von Hippel\u2013Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468\u2013472 (2001).","journal-title":"Science"},{"key":"BFnrc3844_CR45","doi-asserted-by":"publisher","first-page":"9630","DOI":"10.1073\/pnas.181341498","volume":"98","author":"F Yu","year":"2001","unstructured":"Yu, F., White, S. B., Zhao, Q. & Lee, F. S. HIF-1\u03b1 binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl Acad. Sci. USA 98, 9630\u20139635 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207\u2013214 (2012).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrc3844_CR47","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1073\/pnas.0810067106","volume":"106","author":"X Xia","year":"2009","unstructured":"Xia, X. et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl Acad. Sci. USA 106, 4260\u20134265 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR48","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","volume":"117","author":"J Schodel","year":"2011","unstructured":"Schodel, J. et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP\u2013seq. Blood 117, e207\u2013e217 (2011).","journal-title":"Blood"},{"key":"BFnrc3844_CR49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1056\/NEJMra1011165","volume":"365","author":"GL Semenza","year":"2011","unstructured":"Semenza, G. L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365, 537\u2013547 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3844_CR50","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.2174\/138161209789649367","volume":"15","author":"ME Crosby","year":"2009","unstructured":"Crosby, M. E., Devlin, C. M., Glazer, P. M., Calin, G. A. & Ivan, M. Emerging roles of microRNAs in the molecular responses to hypoxia. Curr. Pharm. Des. 15, 3861\u20133866 (2009).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrc3844_CR51","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.molcel.2011.07.012","volume":"43","author":"MZ Wu","year":"2011","unstructured":"Wu, M. Z. et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol. Cell 43, 811\u2013822 (2011).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR52","doi-asserted-by":"publisher","first-page":"36542","DOI":"10.1074\/jbc.M804578200","volume":"283","author":"S Beyer","year":"2008","unstructured":"Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V. & Staller, P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 283, 36542\u201336552 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3844_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1042\/BJ20081238","volume":"416","author":"PJ Pollard","year":"2008","unstructured":"Pollard, P. J. et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1\u03b1. Biochem. J. 416, 387\u2013394 (2008).","journal-title":"Biochem. J."},{"key":"BFnrc3844_CR54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.onc.1209062","volume":"25","author":"K Knauth","year":"2006","unstructured":"Knauth, K., Bex, C., Jemth, P. & Buchberger, A. Renal cell carcinoma risk in type 2 von Hippel\u2013Lindau disease correlates with defects in pVHL stability and HIF-1\u03b1 interactions. Oncogene 25, 370\u2013377 (2006).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR55","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/hmg\/10.10.1029","volume":"10","author":"SC Clifford","year":"2001","unstructured":"Clifford, S. C. et al. Contrasting effects on HIF-1\u03b1 regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel\u2013Lindau disease. Hum. Mol. Genet. 10, 1029\u20131038 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3844_CR56","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1128\/MCB.00282-07","volume":"27","author":"L Li","year":"2007","unstructured":"Li, L. et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol. Cell. Biol. 27, 5381\u20135392 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/bbrc.1999.1347","volume":"263","author":"H Okuda","year":"1999","unstructured":"Okuda, H. et al. Direct interaction of the \u03b2-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem. Biophys. Res. Commun. 263, 491\u2013497 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc3844_CR58","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1073\/pnas.0436037100","volume":"100","author":"AV Kuznetsova","year":"2003","unstructured":"Kuznetsova, A. V. et al. von Hippel\u2013Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc. Natl Acad. Sci. USA 100, 2706\u20132711 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR59","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","volume":"23","author":"CJ Hu","year":"2003","unstructured":"Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation. Mol. Cell. Biol. 23, 9361\u20139374 (2003).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR60","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel\u2013Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675\u20135686 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR61","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-05-2519","volume":"66","author":"VA Carroll","year":"2006","unstructured":"Carroll, V. A. & Ashcroft, M. Role of hypoxia-inducible factor (HIF)-1\u03b1 versus HIF-2\u03b1 in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel\u2013Lindau function: implications for targeting the HIF pathway. Cancer Res. 66, 6264\u20136270 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2012","unstructured":"Keith, B., Johnson, R. S. & Simon, M. C. HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nature Rev. Cancer 12, 9\u201322 (2012).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3844_CR63","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1038\/sj.emboj.7601300","volume":"25","author":"WY Kim","year":"2006","unstructured":"Kim, W. Y. et al. Failure to prolyl hydroxylate hypoxia-inducible factor \u03b1 phenocopies VHL inactivation in vivo. EMBO J. 25, 4650\u20134662 (2006).","journal-title":"EMBO J."},{"key":"BFnrc3844_CR64","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1172\/JCI30117","volume":"117","author":"EB Rankin","year":"2007","unstructured":"Rankin, E. B. et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 117, 1068\u20131077 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrc3844_CR65","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/MCB.25.8.3163-3172.2005","volume":"25","author":"EB Rankin","year":"2005","unstructured":"Rankin, E. B. et al. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel\u2013Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol. 25, 3163\u20133172 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR66","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1128\/MCB.00200-09","volume":"29","author":"EB Rankin","year":"2009","unstructured":"Rankin, E. B. et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell. Biol. 29, 4527\u20134538 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR67","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1038\/onc.2008.160","volume":"27","author":"EB Rankin","year":"2008","unstructured":"Rankin, E. B. et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27, 5354\u20135358 (2008).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR68","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, e83 (2003).","journal-title":"PLoS Biol."},{"key":"BFnrc3844_CR69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1541-7786.89.2.2","volume":"2","author":"M Zimmer","year":"2004","unstructured":"Zimmer, M., Doucette, D., Siddiqui, N. & Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL\u2212\/\u2212 tumors. Mol. Cancer Res. 2, 89\u201395 (2004).","journal-title":"Mol. Cancer Res."},{"key":"BFnrc3844_CR70","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel\u2013Lindau protein. Cancer Cell 1, 237\u2013246 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrc3844_CR71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"14","author":"JD Gordan","year":"2008","unstructured":"Gordan, J. D. et al. HIF\u03b1 effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435\u2013446 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrc3844_CR72","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","volume":"1","author":"C Shen","year":"2011","unstructured":"Shen, C. et al. Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222\u2013235 (2011).","journal-title":"Cancer Discov."},{"key":"BFnrc3844_CR73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","volume":"1","author":"JK Maranchie","year":"2002","unstructured":"Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1\u03b1 to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247\u2013255 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrc3844_CR74","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1158\/0008-5472.CAN-12-3983","volume":"73","author":"L Fu","year":"2013","unstructured":"Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M. & Gudas, L. J. Activation of HIF2\u03b1 in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res. 73, 2916\u20132925 (2013).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR75","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1158\/0008-5472.CAN-11-1745","volume":"71","author":"L Fu","year":"2011","unstructured":"Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M. & Gudas, L. J. Generation of a mouse model of Von Hippel\u2013Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1\u03b1. Cancer Res. 71, 6848\u20136856 (2011).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR76","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.molcel.2012.09.017","volume":"48","author":"A Elorza","year":"2012","unstructured":"Elorza, A. et al. HIF2\u03b1 acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol. Cell 48, 681\u2013691 (2012).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR77","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pbio.0020289","volume":"2","author":"T Bishop","year":"2004","unstructured":"Bishop, T. et al. Genetic analysis of pathways regulated by the von Hippel\u2013Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol. 2, e289 (2004).","journal-title":"PLoS Biol."},{"key":"BFnrc3844_CR78","first-page":"453","volume":"1","author":"Y Jiang","year":"2003","unstructured":"Jiang, Y. et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol. Cancer Res. 1, 453\u2013462 (2003).","journal-title":"Mol. Cancer Res."},{"key":"BFnrc3844_CR79","first-page":"3803","volume":"62","author":"M Zatyka","year":"2002","unstructured":"Zatyka, M. et al. Identification of cyclin D1 and other novel targets for the von Hippel\u2013Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel\u2013Lindau disease. Cancer Res. 62, 3803\u20133811 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR80","doi-asserted-by":"publisher","first-page":"16484","DOI":"10.1073\/pnas.0806574105","volume":"105","author":"A Bommi-Reddy","year":"2008","unstructured":"Bommi-Reddy, A. et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL\u2212\/\u2212 cancer cells detected in a pilot synthetic lethal screen. Proc. Natl Acad. Sci. USA 105, 16484\u201316489 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR81","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-5793(03)01392-9","volume":"556","author":"HA Bluyssen","year":"2004","unstructured":"Bluyssen, H. A. et al. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 556, 137\u2013142 (2004).","journal-title":"FEBS Lett."},{"key":"BFnrc3844_CR82","first-page":"133","volume":"134","author":"JS Green","year":"1986","unstructured":"Green, J. S., Bowmer, M. I. & Johnson, G. J. Von Hippel\u2013Lindau disease in a Newfoundland kindred. CMAJ 134, 133\u2013138 (1986).","journal-title":"CMAJ"},{"key":"BFnrc3844_CR83","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/nar\/26.1.256","volume":"26","author":"C Beroud","year":"1998","unstructured":"Beroud, C. et al. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 26, 256\u2013258 (1998).","journal-title":"Nucleic Acids Res."},{"key":"BFnrc3844_CR84","first-page":"521","volume":"31","author":"M Nordstrom-O'Brien","year":"2010","unstructured":"Nordstrom-O'Brien, M. et al. Genetic analysis of von Hippel\u2013Lindau disease. Hum. Mutat. 31, 521\u2013537 (2010).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR85","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/humu.20496","volume":"28","author":"A Cascon","year":"2007","unstructured":"Cascon, A. et al. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel\u2013Lindau patients. Hum. Mutat. 28, 613\u2013621 (2007).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/humu.10302","volume":"23","author":"JK Maranchie","year":"2004","unstructured":"Maranchie, J. K. et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum. Mutat. 23, 40\u201346 (2004).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR87","doi-asserted-by":"crossref","unstructured":"McNeill, A. et al. Genotype-phenotype correlations in VHL exon deletions. Am. J. Med. Genet. A 149A, 2147\u20132151 (2009).","DOI":"10.1002\/ajmg.a.33023"},{"key":"BFnrc3844_CR88","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/humu.20948","volume":"30","author":"G Franke","year":"2009","unstructured":"Franke, G. et al. Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and genotype\u2013phenotype correlations in VHL patients. Hum. Mutat. 30, 776\u2013786 (2009).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR89","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/humu.20385","volume":"28","author":"KR Ong","year":"2007","unstructured":"Ong, K. R. et al. Genotype\u2013phenotype correlations in von Hippel\u2013Lindau disease. Hum. Mutat. 28, 143\u2013149 (2007).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR90","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/humu.20082","volume":"24","author":"C Gallou","year":"2004","unstructured":"Gallou, C. et al. Genotype\u2013phenotype correlation in von Hippel\u2013Lindau families with renal lesions. Hum. Mutat. 24, 215\u2013224 (2004).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR91","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A","volume":"13","author":"C Gallou","year":"1999","unstructured":"Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464\u2013475 (1999).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR92","doi-asserted-by":"publisher","first-page":"e6037","DOI":"10.1371\/journal.pone.0006037","volume":"4","author":"C Ricketts","year":"2009","unstructured":"Ricketts, C., Zeegers, M. P., Lubinski, J. & Maher, E. R. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS ONE 4, e6037 (2009).","journal-title":"PLoS ONE"},{"key":"BFnrc3844_CR93","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1086\/302037","volume":"63","author":"AR Webster","year":"1998","unstructured":"Webster, A. R., Richards, F. M., MacRonald, F. E., Moore, A. T. & Maher, E. R. An analysis of phenotypic variation in the familial cancer syndrome von Hippel\u2013Lindau disease: evidence for modifier effects. Am. J. Hum. Genet. 63, 1025\u20131035 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrc3844_CR94","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang, S. O. et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genet. 32, 614\u2013621 (2002).","journal-title":"Nature Genet."},{"key":"BFnrc3844_CR95","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1182\/blood-2002-06-1843","volume":"101","author":"YD Pastore","year":"2003","unstructured":"Pastore, Y. D. et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101, 1591\u20131595 (2003).","journal-title":"Blood"},{"key":"BFnrc3844_CR96","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/ejh.12170","volume":"91","author":"C Bento","year":"2013","unstructured":"Bento, C. et al. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is\/are the missing gene(s)?). Eur. J. Haematol. 91, 361\u2013368 (2013).","journal-title":"Eur. J. Haematol."},{"key":"BFnrc3844_CR97","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1182\/blood-2012-11-469296","volume":"121","author":"L Lanikova","year":"2013","unstructured":"Lanikova, L. et al. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. Blood 121, 3918\u20133924 (2013).","journal-title":"Blood"},{"key":"BFnrc3844_CR98","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3324\/haematol.2012.070508","volume":"98","author":"NL Tomasic","year":"2013","unstructured":"Tomasic, N. L. et al. The phenotype of polycythemia due to Croatian homozygous VHL (571C&gt;G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C&gt;T:R200W). Haematologica 98, 560\u2013567 (2013).","journal-title":"Haematologica"},{"key":"BFnrc3844_CR99","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/humu.22448","volume":"35","author":"C Bento","year":"2014","unstructured":"Bento, C. et al. Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum. Mutat. 35, 15\u201326 (2014).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR100","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1200\/JCO.2011.38.6797","volume":"30","author":"S Capodimonti","year":"2012","unstructured":"Capodimonti, S. et al. Von Hippel\u2013Lindau disease and erythrocytosis. J. Clin. Oncol. 30, e137\u2013e139 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3844_CR101","first-page":"3879","volume":"117","author":"MM Hickey","year":"2007","unstructured":"Hickey, M. M., Lam, J. C., Bezman, N. A., Rathmell, W. K. & Simon, M. C. von Hippel\u2013Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2\u03b1 signaling and splenic erythropoiesis. J. Clin. Invest. 117, 3879\u20133889 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrc3844_CR102","doi-asserted-by":"publisher","first-page":"6449","DOI":"10.1182\/blood-2008-07-167890","volume":"113","author":"E van Rooijen","year":"2009","unstructured":"van Rooijen, E. et al. Zebrafish mutants in the von Hippel\u2013Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. Blood 113, 6449\u20136460 (2009).","journal-title":"Blood"},{"key":"BFnrc3844_CR103","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V75.3.577.577","volume":"75","author":"JL Da Silva","year":"1990","unstructured":"Da Silva, J. L. et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 75, 577\u2013582 (1990).","journal-title":"Blood"},{"key":"BFnrc3844_CR104","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V92.9.3388","volume":"92","author":"M Krieg","year":"1998","unstructured":"Krieg, M., Marti, H. H. & Plate, K. H. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel\u2013Lindau tumor suppressor gene loss of function. Blood 92, 3388\u20133393 (1998).","journal-title":"Blood"},{"key":"BFnrc3844_CR105","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nm.2370","volume":"17","author":"RC Russell","year":"2011","unstructured":"Russell, R. C. et al. Loss of JAK2 regulation via a heterodimeric VHL\u2013SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nature Med. 17, 845\u2013853 (2011).","journal-title":"Nature Med."},{"key":"BFnrc3844_CR106","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/JCI36362","volume":"120","author":"MM Hickey","year":"2010","unstructured":"Hickey, M. M. et al. The von Hippel\u2013Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J. Clin. Invest. 120, 827\u2013839 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrc3844_CR107","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1073\/pnas.0608382104","volume":"104","author":"M Gruber","year":"2007","unstructured":"Gruber, M. et al. Acute postnatal ablation of Hif-2\u03b1 results in anemia. Proc. Natl Acad. Sci. USA 104, 2301\u20132306 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR108","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1182\/blood-2004-05-1695","volume":"105","author":"M Scortegagna","year":"2005","unstructured":"Scortegagna, M. et al. HIF-2\u03b1 regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105, 3133\u20133140 (2005).","journal-title":"Blood"},{"key":"BFnrc3844_CR109","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr.","year":"1971","unstructured":"Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820\u2013823 (1971).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR110","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/hmg\/3.12.2169","volume":"3","author":"K Foster","year":"1994","unstructured":"Foster, K. et al. Somatic mutations of the von Hippel\u2013Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3, 2169\u20132173 (1994).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3844_CR111","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85\u201390 (1994).","journal-title":"Nature Genet."},{"key":"BFnrc3844_CR112","first-page":"703","volume":"41","author":"T Shuin","year":"1995","unstructured":"Shuin, T. et al. [Results of mutation analyses of von Hippel\u2013Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom]. Hinyokika Kiyo. 41, 703\u2013707 (1995) (in Japanese).","journal-title":"Hinyokika Kiyo."},{"key":"BFnrc3844_CR113","first-page":"1092","volume":"55","author":"JM Whaley","year":"1994","unstructured":"Whaley, J. M. et al. Germ-line mutations in the von Hippel\u2013Lindau tumor-suppressor gene are similar to somatic von Hippel\u2013Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55, 1092\u20131102 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrc3844_CR114","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrclinonc.2010.42","volume":"7","author":"L Gossage","year":"2010","unstructured":"Gossage, L. & Eisen, T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nature Rev. Clin. Oncol. 7, 277\u2013288 (2010).","journal-title":"Nature Rev. Clin. Oncol."},{"key":"BFnrc3844_CR115","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-12-3886","volume":"19","author":"AA Hakimi","year":"2013","unstructured":"Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA Research Network. Clin. Cancer Res. 19, 3259\u20133267 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3844_CR116","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pena-Llopis","year":"2012","unstructured":"Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nature Genet. 44, 751\u2013759 (2012).","journal-title":"Nature Genet."},{"key":"BFnrc3844_CR117","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","volume":"469","author":"I Varela","year":"2011","unstructured":"Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539\u2013542 (2011).","journal-title":"Nature"},{"key":"BFnrc3844_CR118","unstructured":"COSMIC. Genes mutated in clear renal cell carcinoma. Catalogue of Somatic Mutations in Cancer [online] , (2014)."},{"key":"BFnrc3844_CR119","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/gcc.22116","volume":"53","author":"L Gossage","year":"2014","unstructured":"Gossage, L. et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 53, 38\u201351 (2014).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrc3844_CR120","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","volume":"15","author":"AC Young","year":"2009","unstructured":"Young, A. C. et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin. Cancer Res. 15, 7582\u20137592 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3844_CR121","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1158\/0008-5472.CAN-11-0757","volume":"71","author":"MP Rechsteiner","year":"2011","unstructured":"Rechsteiner, M. P. et al. VHL gene mutations and their effects on hypoxia inducible factor HIF\u03b1: identification of potential driver and passenger mutations. Cancer Res. 71, 5500\u20135511 (2011).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR122","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/jnnp.70.5.644","volume":"70","author":"S Glasker","year":"2001","unstructured":"Glasker, S. et al. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J. Neurol. Neurosurg. Psychiatry 70, 644\u2013648 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrc3844_CR123","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0","volume":"179","author":"J Oberstrass","year":"1996","unstructured":"Oberstrass, J., Reifenberger, G., Reifenberger, J., Wechsler, W. & Collins, V. P. Mutation of the Von Hippel\u2013Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J. Pathol. 179, 151\u2013156 (1996).","journal-title":"J. Pathol."},{"key":"BFnrc3844_CR124","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/jmg.32.12.934","volume":"32","author":"C Eng","year":"1995","unstructured":"Eng, C. et al. Mutations in the RET proto-oncogene and the von Hippel\u2013Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J. Med. Genet. 32, 934\u2013937 (1995).","journal-title":"J. Med. Genet."},{"key":"BFnrc3844_CR125","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HP Neumann","year":"2002","unstructured":"Neumann, H. P. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459\u20131466 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3844_CR126","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-13-0491","volume":"19","author":"TK Choueiri","year":"2013","unstructured":"Choueiri, T. K. et al. The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin. Cancer Res. 19, 5218 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3844_CR127","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-09-3343","volume":"16","author":"C Pena","year":"2010","unstructured":"Pena, C., Lathia, C., Shan, M., Escudier, B. & Bukowski, R. M. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Cancer Res. 16, 4853\u20134863 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3844_CR128","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.juro.2008.05.015","volume":"180","author":"TK Choueiri","year":"2008","unstructured":"Choueiri, T. K. et al. von Hippel\u2013Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860\u2013865 (2008).","journal-title":"J. Urol."},{"key":"BFnrc3844_CR129","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1093\/annonc\/mdt219","volume":"24","author":"J Garcia-Donas","year":"2013","unstructured":"Garcia-Donas, J. et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann. Oncol. 24, 2409\u20132414 (2013).","journal-title":"Ann. Oncol."},{"key":"BFnrc3844_CR130","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1464-410X.2006.06376.x","volume":"98","author":"BI Rini","year":"2006","unstructured":"Rini, B. I. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel\u2013Lindau gene status. BJU Int. 98, 756\u2013762 (2006).","journal-title":"BJU Int."},{"key":"BFnrc3844_CR131","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11523-006-0039-9","volume":"2","author":"S Gad","year":"2007","unstructured":"Gad, S. et al. Somatic von Hippel\u2013Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol. 2, 3\u20136 (2007).","journal-title":"Target Oncol."},{"key":"BFnrc3844_CR132","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","volume":"5","author":"D Cho","year":"2007","unstructured":"Cho, D. et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin Cancer 5, 379\u2013385 (2007).","journal-title":"Clin. Genitourin Cancer"},{"key":"BFnrc3844_CR133","first-page":"859","volume":"13","author":"JH Kim","year":"2005","unstructured":"Kim, J. H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 13, 859\u2013864 (2005).","journal-title":"Oncol. Rep."},{"key":"BFnrc3844_CR134","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature08672","volume":"463","author":"GL Dalgliesh","year":"2010","unstructured":"Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360\u2013363 (2010).","journal-title":"Nature"},{"key":"BFnrc3844_CR135","first-page":"11","volume":"10","author":"SA Forbes","year":"2008","unstructured":"Forbes, S. A. et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. 10, 11 (2008).","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"BFnrc3844_CR136","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","volume":"1","author":"SJ Mandriota","year":"2002","unstructured":"Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459\u2013468 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrc3844_CR137","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-05-3241","volume":"66","author":"EB Rankin","year":"2006","unstructured":"Rankin, E. B., Tomaszewski, J. E. & Haase, V. H. Renal cyst development in mice with conditional inactivation of the von Hippel\u2013Lindau tumor suppressor. Cancer Res. 66, 2576\u20132583 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR138","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1098-2264(199708)19:4<228::AID-GCC4>3.0.CO;2-Z","volume":"19","author":"A van den Berg","year":"1997","unstructured":"van den Berg, A. et al. Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chromosomes Cancer 19, 228\u2013232 (1997).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrc3844_CR139","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#","volume":"22","author":"SC Clifford","year":"1998","unstructured":"Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. & Maher, E. R. Inactivation of the von Hippel\u2013Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22, 200\u2013209 (1998).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrc3844_CR140","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng.1014","volume":"44","author":"G Guo","year":"2012","unstructured":"Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nature Genet. 44, 17\u201319 (2012).","journal-title":"Nature Genet."},{"key":"BFnrc3844_CR141","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CJ Creighton","year":"2013","unstructured":"Creighton, C. J. et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"BFnrc3844_CR142","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G van Haaften","year":"2009","unstructured":"van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. 41, 521\u2013523 (2009).","journal-title":"Nature Genet."},{"key":"BFnrc3844_CR143","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1158\/0008-5472.CAN-10-0120","volume":"70","author":"G Duns","year":"2010","unstructured":"Duns, G. et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70, 4287\u20134291 (2010).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR144","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1101\/gr.123109.111","volume":"22","author":"L Wang","year":"2012","unstructured":"Wang, L. et al. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res. 22, 208\u2013219 (2012).","journal-title":"Genome Res."},{"key":"BFnrc3844_CR145","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/humu.22090","volume":"33","author":"G Duns","year":"2012","unstructured":"Duns, G. et al. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum. Mutat. 33, 1059\u20131062 (2012).","journal-title":"Hum. Mutat."},{"key":"BFnrc3844_CR146","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","volume":"32","author":"J Brugarolas","year":"2014","unstructured":"Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 32, 1968\u20131976 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3844_CR147","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.eururo.2012.09.005","volume":"63","author":"AA Hakimi","year":"2012","unstructured":"Hakimi, A. A. et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol. 63, 848\u2013854 (2012).","journal-title":"Eur. Urol."},{"key":"BFnrc3844_CR148","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","DOI":"10.1038\/nature12222"},{"key":"BFnrc3844_CR149","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3844_CR150","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrclinonc.2012.59","volume":"9","author":"B Escudier","year":"2012","unstructured":"Escudier, B., Szczylik, C., Porta, C. & Gore, M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature Rev. Clin. Oncol. 9, 327\u2013337 (2012).","journal-title":"Nature Rev. Clin. Oncol."},{"key":"BFnrc3844_CR151","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nchembio.1185","volume":"9","author":"TH Scheuermann","year":"2013","unstructured":"Scheuermann, T. H. et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nature Chem. Biol. 9, 271\u2013276 (2013).","journal-title":"Nature Chem. Biol."},{"key":"BFnrc3844_CR152","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1073\/pnas.0808092106","volume":"106","author":"TH Scheuermann","year":"2009","unstructured":"Scheuermann, T. H. et al. Artificial ligand binding within the HIF2\u03b1 PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106, 450\u2013455 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR153","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1021\/cb700110z","volume":"2","author":"NG Nickols","year":"2007","unstructured":"Nickols, N. G., Jacobs, C. S., Farkas, M. E. & Dervan, P. B. Modulating hypoxia-inducible transcription by disrupting the HIF-1\u2013DNA interface. ACS Chem. Biol. 2, 561\u2013571 (2007).","journal-title":"ACS Chem. Biol."},{"key":"BFnrc3844_CR154","doi-asserted-by":"publisher","first-page":"8539","DOI":"10.1016\/j.bmc.2006.08.028","volume":"14","author":"A Viger","year":"2006","unstructured":"Viger, A. & Dervan, P. B. Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site. Bioorg. Med. Chem. 14, 8539\u20138549 (2006).","journal-title":"Bioorg. Med. Chem."},{"key":"BFnrc3844_CR155","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1126\/stke.2842005pe23","volume":"2005","author":"C Vinson","year":"2005","unstructured":"Vinson, C. A rationally designed small molecule that inhibits the HIF-1\u03b1\u2013ARNT heterodimer from binding to DNA in vivo. Sci. STKE 2005, e23 (2005).","journal-title":"Sci. STKE"},{"key":"BFnrc3844_CR156","doi-asserted-by":"publisher","first-page":"17910","DOI":"10.1073\/pnas.0909353106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106, 17910\u201317915 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3844_CR157","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","volume":"32","author":"M Zimmer","year":"2008","unstructured":"Zimmer, M. et al. Small-molecule inhibitors of HIF-2a translation link its 5\u2032UTR iron-responsive element to oxygen sensing. Mol. Cell 32, 838\u2013848 (2008).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR158","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1248\/cpb.59.1178","volume":"59","author":"HR Bokesch","year":"2011","unstructured":"Bokesch, H. R. et al. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. Chem. Pharm. Bull. (Tokyo) 59, 1178\u20131179 (2011).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"BFnrc3844_CR159","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.bmcl.2011.01.127","volume":"21","author":"T Grkovic","year":"2011","unstructured":"Grkovic, T. et al. Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2\u03b1 induced gene expression. Bioorg. Med. Chem. Lett. 21, 2113\u20132115 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrc3844_CR160","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1087057106289234","volume":"11","author":"GM Woldemichael","year":"2006","unstructured":"Woldemichael, G. M. et al. Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. J. Biomol. Screen 11, 678\u2013687 (2006).","journal-title":"J. Biomol. Screen"},{"key":"BFnrc3844_CR161","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1053\/j.seminoncol.2006.06.001","volume":"33","author":"WY Kim","year":"2006","unstructured":"Kim, W. Y. & Kaelin, W. G. Jr. Molecular pathways in renal cell carcinoma \u2014 rationale for targeted treatment. Semin. Oncol. 33, 588\u2013595 (2006).","journal-title":"Semin. Oncol."},{"key":"BFnrc3844_CR162","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr.","year":"2005","unstructured":"Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689\u2013698 (2005).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3844_CR163","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2008.06.004","volume":"14","author":"S Turcotte","year":"2008","unstructured":"Turcotte, S. et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14, 90\u2013102 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrc3844_CR164","first-page":"94ra70","volume":"3","author":"DA Chan","year":"2011","unstructured":"Chan, D. A. et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrc3844_CR165","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1593\/neo.12852","volume":"14","author":"GM Woldemichael","year":"2012","unstructured":"Woldemichael, G. M., Turbyville, T. J., Vasselli, J. R., Linehan, W. M. & McMahon, J. B. Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. Neoplasia 14, 771\u2013777 (2012).","journal-title":"Neoplasia"},{"key":"BFnrc3844_CR166","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1097-2765(00)80233-6","volume":"4","author":"DE Feldman","year":"1999","unstructured":"Feldman, D. E., Thulasiraman, V., Ferreyra, R. G. & Frydman, J. Formation of the VHL\u2013elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol. Cell 4, 1051\u20131061 (1999).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR167","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1002\/j.1460-2075.1992.tb05582.x","volume":"11","author":"J Frydman","year":"1992","unstructured":"Frydman, J. et al. Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits. EMBO J. 11, 4767\u20134778 (1992).","journal-title":"EMBO J."},{"key":"BFnrc3844_CR168","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2005.03.024","volume":"121","author":"AJ McClellan","year":"2005","unstructured":"McClellan, A. J., Scott, M. D. & Frydman, J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 121, 739\u2013748 (2005).","journal-title":"Cell"},{"key":"BFnrc3844_CR169","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/1087057112436557","volume":"17","author":"Z Ding","year":"2012","unstructured":"Ding, Z. et al. Agents that stabilize mutated von Hippel\u2013Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J. Biomol. Screen 17, 572\u2013580 (2012).","journal-title":"J. Biomol. Screen"},{"key":"BFnrc3844_CR170","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-13-3213","volume":"74","author":"Z Ding","year":"2014","unstructured":"Ding, Z. et al. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Res. 74, 3127\u20133136 (2014).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR171","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/onc.2011.266","volume":"31","author":"X Niu","year":"2012","unstructured":"Niu, X. et al. The von Hippel\u2013Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31, 776\u2013786 (2012).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR172","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1158\/0008-5472.CAN-04-4406","volume":"65","author":"D Zagzag","year":"2005","unstructured":"Zagzag, D. et al. Stromal cell-derived factor-1\u03b1 and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel\u2013Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65, 6178\u20136188 (2005).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR173","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01874","volume":"425","author":"P Staller","year":"2003","unstructured":"Staller, P. et al. Chemokine receptor CXCR4 downregulated by von Hippel\u2013Lindau tumour suppressor pVHL. Nature 425, 307\u2013311 (2003).","journal-title":"Nature"},{"key":"BFnrc3844_CR174","first-page":"226","volume":"58","author":"B Knebelmann","year":"1998","unstructured":"Knebelmann, B., Ananth, S., Cohen, H. T. & Sukhatme, V. P. Transforming growth factor \u03b1 is a target for the von Hippel\u2013Lindau tumor suppressor. Cancer Res. 58, 226\u2013231 (1998).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR175","doi-asserted-by":"publisher","first-page":"44966","DOI":"10.1074\/jbc.M305502200","volume":"278","author":"L Gunaratnam","year":"2003","unstructured":"Gunaratnam, L. et al. Hypoxia inducible factor activates the transforming growth factor-\u03b1\/epidermal growth factor receptor growth stimulatory pathway in VHL\u2212\/\u2212 renal cell carcinoma cells. J. Biol. Chem. 278, 44966\u201344974 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3844_CR176","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1074\/jbc.M611648200","volume":"282","author":"A Grosfeld","year":"2007","unstructured":"Grosfeld, A. et al. Interaction of hydroxylated collagen IV with the von Hippel\u2013Lindau tumor suppressor. J. Biol. Chem. 282, 13264\u201313269 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3844_CR177","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1128\/MCB.00892-06","volume":"27","author":"AJ Evans","year":"2007","unstructured":"Evans, A. J. et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol. Cell. Biol. 27, 157\u2013169 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR178","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1091\/mbc.e08-06-0566","volume":"20","author":"SK Harten","year":"2009","unstructured":"Harten, S. K. et al. Regulation of renal epithelial tight junctions by the von Hippel\u2013Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. Mol. Biol. Cell 20, 1089\u20131101 (2009).","journal-title":"Mol. Biol. Cell"},{"key":"BFnrc3844_CR179","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1476-4598-5-66","volume":"5","author":"BL Petrella","year":"2006","unstructured":"Petrella, B. L. & Brinckerhoff, C. E. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol. Cancer 5, 66 (2006).","journal-title":"Mol. Cancer"},{"key":"BFnrc3844_CR180","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/sj.onc.1208305","volume":"24","author":"BL Petrella","year":"2005","unstructured":"Petrella, B. L., Lohi, J. & Brinckerhoff, C. E. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 \u03b1 in von Hippel\u2013Lindau renal cell carcinoma. Oncogene 24, 1043\u20131052 (2005).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR181","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1128\/MCB.26.7.2519-2530.2006","volume":"26","author":"N Tang","year":"2006","unstructured":"Tang, N., Mack, F., Haase, V. H., Simon, M. C. & Johnson, R. S. pVHL function is essential for endothelial extracellular matrix deposition. Mol. Cell. Biol. 26, 2519\u20132530 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR182","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.onc.1210709","volume":"27","author":"G Kurban","year":"2008","unstructured":"Kurban, G. et al. Collagen matrix assembly is driven by the interaction of von Hippel\u2013Lindau tumor suppressor protein with hydroxylated collagen IV \u03b12. Oncogene 27, 1004\u20131012 (2008).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR183","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/0008-5472.CAN-05-2560","volume":"66","author":"G Kurban","year":"2006","unstructured":"Kurban, G., Hudon, V., Duplan, E., Ohh, M. & Pause, A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 66, 1313\u20131319 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR184","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1097-2765(00)80096-9","volume":"1","author":"M Ohh","year":"1998","unstructured":"Ohh, M. et al. The von Hippel\u2013Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959\u2013968 (1998).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR185","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1128\/MCB.24.8.3251-3261.2004","volume":"24","author":"NH Stickle","year":"2004","unstructured":"Stickle, N. H. et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell. Biol. 24, 3251\u20133261 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR186","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1139\/O08-035","volume":"86","author":"Q Ji","year":"2008","unstructured":"Ji, Q. & Burk, R. D. Downregulation of integrins by von Hippel\u2013Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor \u03b1 degradation. Biochem. Cell Biol. 86, 227\u2013234 (2008).","journal-title":"Biochem. Cell Biol."},{"key":"BFnrc3844_CR187","first-page":"2929","volume":"62","author":"MA Esteban-Barragan","year":"2002","unstructured":"Esteban-Barragan, M. A. et al. Role of the von Hippel\u2013Lindau tumor suppressor gene in the formation of \u03b21-integrin fibrillar adhesions. Cancer Res. 62, 2929\u20132936 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR188","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/ncb899","volume":"5","author":"A Hergovich","year":"2003","unstructured":"Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. & Krek, W. Regulation of microtubule stability by the von Hippel\u2013Lindau tumour suppressor protein pVHL. Nature Cell Biol. 5, 64\u201370 (2003).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3844_CR189","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1128\/MCB.00232-06","volume":"26","author":"A Hergovich","year":"2006","unstructured":"Hergovich, A. et al. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol. Cell. Biol. 26, 5784\u20135796 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR190","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ncb1912","volume":"11","author":"CR Thoma","year":"2009","unstructured":"Thoma, C. R. et al. VHL loss causes spindle misorientation and chromosome instability. Nature Cell Biol. 11, 994\u20131001 (2009).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3844_CR191","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.200605092","volume":"175","author":"B Schermer","year":"2006","unstructured":"Schermer, B. et al. The von Hippel\u2013Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. J. Cell Biol. 175, 547\u2013554 (2006).","journal-title":"J. Cell Biol."},{"key":"BFnrc3844_CR192","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1681\/ASN.2006020181","volume":"17","author":"MA Esteban","year":"2006","unstructured":"Esteban, M. A., Harten, S. K., Tran, M. G. & Maxwell, P. H. Formation of primary cilia in the renal epithelium is regulated by the von Hippel\u2013Lindau tumor suppressor protein. J. Am. Soc. Nephrol. 17, 1801\u20131806 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrc3844_CR193","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1158\/0008-5472.CAN-06-0501","volume":"66","author":"MS Lutz","year":"2006","unstructured":"Lutz, M. S. & Burk, R. D. Primary cilium formation requires von Hippel\u2013Lindau gene function in renal-derived cells. Cancer Res. 66, 6903\u20136907 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR194","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.4161\/cc.6.15.4518","volume":"6","author":"CR Thoma","year":"2007","unstructured":"Thoma, C. R., Frew, I. J. & Krek, W. The VHL tumor suppressor: riding tandem with GSK3\u03b2 in primary cilium maintenance. Cell Cycle 6, 1809\u20131813 (2007).","journal-title":"Cell Cycle"},{"key":"BFnrc3844_CR195","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1083\/jcb.201006059","volume":"190","author":"CR Thoma","year":"2010","unstructured":"Thoma, C. R. et al. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. J. Cell Biol. 190, 991\u20131003 (2010).","journal-title":"J. Cell Biol."},{"key":"BFnrc3844_CR196","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2013.02.024","volume":"49","author":"IJ Frew","year":"2013","unstructured":"Frew, I. J., Smole, Z., Thoma, C. R. & Krek, W. Genetic deletion of the long isoform of the von Hippel\u2013Lindau tumour suppressor gene product alters microtubule dynamics. Eur. J. Cancer 49, 2433\u20132440 (2013).","journal-title":"Eur. J. Cancer"},{"key":"BFnrc3844_CR197","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1158\/0008-5472.CAN-09-1770","volume":"69","author":"AM Roberts","year":"2009","unstructured":"Roberts, A. M. et al. Suppression of hypoxia-inducible factor 2\u03b1 restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 69, 9056\u20139064 (2009).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR198","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1006\/excr.1998.4193","volume":"244","author":"WG An","year":"1998","unstructured":"An, W. G., Chuman, Y., Fojo, T. & Blagosklonny, M. V. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp. Cell Res. 244, 54\u201360 (1998).","journal-title":"Exp. Cell Res."},{"key":"BFnrc3844_CR199","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molcel.2004.11.019","volume":"17","author":"N Sanchez-Puig","year":"2005","unstructured":"Sanchez-Puig, N., Veprintsev, D. B. & Fersht, A. R. Binding of natively unfolded HIF-1\u03b1 ODD domain to p53. Mol. Cell 17, 11\u201321 (2005).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR200","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature09141","volume":"465","author":"A Sendoel","year":"2010","unstructured":"Sendoel, A., Kohler, I., Fellmann, C., Lowe, S. W. & Hengartner, M. O. HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 465, 577\u2013583 (2010).","journal-title":"Nature"},{"key":"BFnrc3844_CR201","first-page":"7076","volume":"63","author":"H Qi","year":"2003","unstructured":"Qi, H. & Ohh, M. The von Hippel\u2013Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-\u03baB-dependent antiapoptotic pathway. Cancer Res. 63, 7076\u20137080 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR202","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/sj.onc.1208348","volume":"24","author":"J An","year":"2005","unstructured":"An, J., Fisher, M. & Rettig, M. B. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-\u03baB-dependent mechanism. Oncogene 24, 1563\u20131570 (2005).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR203","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/0008-5472.CAN-09-2211","volume":"70","author":"AJ Pantuck","year":"2010","unstructured":"Pantuck, A. J., An, J., Liu, H. & Rettig, M. B. NF-\u03baB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel\u2013Lindau inactivation in renal cell carcinomas. Cancer Res. 70, 752\u2013761 (2010).","journal-title":"Cancer Res."},{"key":"BFnrc3844_CR204","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molcel.2006.04.006","volume":"22","author":"JS Roe","year":"2006","unstructured":"Roe, J. S. et al. p53 stabilization and transactivation by a von Hippel\u2013Lindau protein. Mol. Cell 22, 395\u2013405 (2006).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR205","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.4161\/cc.5.18.3247","volume":"5","author":"JS Roe","year":"2006","unstructured":"Roe, J. S. & Youn, H. D. The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 5, 2054\u20132056 (2006).","journal-title":"Cell Cycle"},{"key":"BFnrc3844_CR206","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2007.09.010","volume":"28","author":"H Yang","year":"2007","unstructured":"Yang, H. et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-\u03baB agonist Card9 by CK2. Mol. Cell 28, 15\u201327 (2007).","journal-title":"Mol. Cell"},{"key":"BFnrc3844_CR207","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ccr.2005.06.015","volume":"8","author":"S Lee","year":"2005","unstructured":"Lee, S. et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8, 155\u2013167 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrc3844_CR208","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/ncb1699","volume":"10","author":"AP Young","year":"2008","unstructured":"Young, A. P. et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biol. 10, 361\u2013369 (2008).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3844_CR209","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1128\/MCB.01618-09","volume":"30","author":"SM Welford","year":"2010","unstructured":"Welford, S. M., Dorie, M. J., Li, X., Haase, V. H. & Giaccia, A. J. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol. Cell. Biol. 30, 4595\u20134603 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR210","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/MCB.01231-07","volume":"28","author":"O Mikhaylova","year":"2008","unstructured":"Mikhaylova, O. et al. The von Hippel\u2013Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol. Cell. Biol. 28, 2701\u20132717 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR211","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/carcin\/bgn275","volume":"30","author":"S Danilin","year":"2009","unstructured":"Danilin, S. et al. von Hippel\u2013Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. Carcinogenesis 30, 387\u2013396 (2009).","journal-title":"Carcinogenesis"},{"key":"BFnrc3844_CR212","doi-asserted-by":"publisher","first-page":"7850","DOI":"10.1038\/sj.onc.1208912","volume":"24","author":"K Datta","year":"2005","unstructured":"Datta, K. et al. Role of elongin-binding domain of von Hippel\u2013Lindau gene product on HuR-mediated VPF\/VEGF mRNA stability in renal cell carcinoma. Oncogene 24, 7850\u20137858 (2005).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR213","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1128\/MCB.23.20.7083-7095.2003","volume":"23","author":"S Galban","year":"2003","unstructured":"Galban, S. et al. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol. Cell. Biol. 23, 7083\u20137095 (2003).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR214","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jcb.10152","volume":"85","author":"LA Rafty","year":"2002","unstructured":"Rafty, L. A. & Khachigian, L. M. von Hippel\u2013Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. J. Cell Biochem. 85, 490\u2013495 (2002).","journal-title":"J. Cell Biochem."},{"key":"BFnrc3844_CR215","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/bbrc.1999.1767","volume":"266","author":"HT Cohen","year":"1999","unstructured":"Cohen, H. T. et al. An important von Hippel\u2013Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem. Biophys. Res. Commun. 266, 43\u201350 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc3844_CR216","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1128\/MCB.17.9.5629","volume":"17","author":"D Mukhopadhyay","year":"1997","unstructured":"Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S. & Sukhatme, V. P. The von Hippel\u2013Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17, 5629\u20135639 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc3844_CR217","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/sj.onc.1206373","volume":"22","author":"M Baba","year":"2003","unstructured":"Baba, M. et al. Loss of von Hippel\u2013Lindau protein causes cell density dependent deregulation of cyclinD1 expression through hypoxia-inducible factor. Oncogene 22, 2728\u20132738 (2003).","journal-title":"Oncogene"},{"key":"BFnrc3844_CR218","first-page":"3014","volume":"62","author":"RS Bindra","year":"2002","unstructured":"Bindra, R. S., Vasselli, J. R., Stearman, R., Linehan, W. M. & Klausner, R. D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62, 3014\u20133019 (2002).","journal-title":"Cancer Res."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc3844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3844","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T22:05:12Z","timestamp":1717625112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc3844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":218,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFnrc3844"],"URL":"https:\/\/doi.org\/10.1038\/nrc3844","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]},"assertion":[{"value":"23 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.E. owns shares with AstraZeneca and has attended advisory boards for Bayer, Pfizer, Roche, GSK and AVEO. He has corporate-sponsored research from AstraZeneca, GSK, Pfizer and Bayer, and received consultation fees from Roche, Bayer, Pfizer, GSK and AVEO. Recently, T.E. has taken part-time leave of absence from the University of Cambridge to act as Chief Clinician Scientist at AstraZeneca. L.G. and E.R.M. have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}